Study on efficacy and safety of levetiracetam administration by nasogastric tube in patients with convulsive status epilepticus

Study on efficacy and safety of levetiracetam administration by nasogastric tube in patients with convulsive status epilepticus - Levetiracetam administration by nasogastric tube in convulsive status epilepticus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010552

Enrollment

Registered

2013-04-21

Start date

2013-04-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Convulsive status epilepticus

Interventions

Levetiracetam administration by the nasogastric tube to patients after convulsion disappeared with diazepam i.v. Levetiracetam administration by the nasogastric tube to patients with convulsion lastin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with convulsive status epilepticus who can be administered by the nasogastric tube

Exclusion criteria

Exclusion criteria: Patinets with non-convulsive status epilepticus Patients required administration of sedative with anticonvulsive effect Systolic blood pressure <60mmHg, >=220mmHg Heart rate <40/min, >=150/min Respiration rate <5/min, >=40/min SpO2 <89% Unstable state of airway Acute coronary syndrome Active gastrointestinal bleeding Patients required intermittent hemodialysis or continuous renal replacement therapy Levetiracetam allergy Patients considered as inappropriate to participate in this study by attending physicians

Design outcomes

Primary

Measure	Time frame
Disappearance of convulsion within 30 min after administration	—

Secondary

Measure	Time frame
Seizure free period of 3-day after administration Side effects Mortality	—

Countries

Japan

Contacts

Public ContactTakafumi Yonemitsu

Wakayama Medical University Department of Emergency and Critical Care Medicine

mirage10261976@mac.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026